Home Alzheimer’s Disease Younger Non-Hispanic Black Patients With AML Have Worse Overall Survival Rates Than...

Younger Non-Hispanic Black Patients With AML Have Worse Overall Survival Rates Than White Patients

White patients with acute myeloid leukemia (AML) appear to benefit more from recent therapy developments compared with non-Hispanic Black patients in the United States, according to data published in Cancer Discovery.1

Specifically, the investigators explain that socioeconomic factors and differences in disease biology both contribute to the survival disparities discovered between each group of patients in this research.

“Our study shows that survival disparities for Black [patients with AML] persist even in the era of improved understanding of the disease and refined genomic classification of AML,” wrote the investigators. “This is particularly noticeable for younger patients, who, in general, have a higher chance of cure.”

Using data compiled from the Surveillance Epidemiology and End Results (SEER) Program, the research team analyzed survival of 25,523 Non-Hispanic Black and…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments